Grammy-winning singer-songwriter Carly Simon announced Monday that she has been diagnosed with Parkinson’s disease [1].
The disclosure from the 83-year-old artist [4] brings public attention to the challenges of aging with a neurodegenerative disorder and emphasizes the importance of medical transparency for public figures.
Simon said the diagnosis followed an extensive evaluation at the Mayo Clinic [2]. In a public statement and letter to her fans, she shared the news to inform her supporters and raise awareness about the realities of living with the condition [3].
Alongside the Parkinson's announcement, reports indicated that Simon was treated for basal cell carcinoma, a form of skin cancer [1, 5]. While some reports focused primarily on the neurological diagnosis, others detailed the skin cancer treatment as part of her recent health journey [1].
Simon addressed the unpredictability of her condition in her statements. "It can be unpredictable," she said [3]. Despite the diagnosis, the singer expressed a determination to continue her life and work. "I have not stopped living," she said [1].
Simon further emphasized her resilience and intent to remain active in the public eye. "I’m not done yet," she said [6]. The singer's decision to go public serves as a personal effort to demystify the disease for others who may be facing similar diagnoses.
Throughout the announcement, Simon framed her experience not as an end to her career, but as a new chapter of navigating health with openness. By detailing her path from the Mayo Clinic evaluation to her current status, she provides a roadmap for fans and fellow artists dealing with chronic illness.
“"I have not stopped living."”
Carly Simon's announcement adds a high-profile voice to the community of artists living with Parkinson's disease. By disclosing both a neurodegenerative condition and a history of skin cancer, Simon highlights the complexity of geriatric health management. Her transparency may encourage others to seek early evaluation at specialized centers like the Mayo Clinic and reduce the stigma associated with cognitive and motor decline in the performing arts.
